Quality · assurance · release control
Quality is a gate, not a badge wall.
NEUVIOR separates operating intent from completed evidence. PHARMORIS remains under controlled development. It is not in production and is not presented as ready for NHS deployment.
01 · Evidence layers
Intent, implementation and independent proof are different states.
A policy, design principle or planned control is not evidence that a production system implements it. An internal test is not an independent certification. A buyer's local approval cannot be inferred from a supplier document.
NEUVIOR's public position should identify what is designed, what exists in the named version, what has been tested, what has been assessed independently and what remains specific to each customer.
Where the evidence is absent, the status remains unknown or incomplete. Marketing language must not convert a plan into an operating fact.
Design intent
The control or quality objective is described, with a clear owner and expected evidence.
Not implementation proofVersion evidence
A named build, test result or controlled record supports a bounded implementation claim.
Scope and date requiredExternal assurance
Independent review is claimed only when the assessor, scope, date and outcome can be evidenced.
No badge inference02 · Release gate
Critical uncertainty stops presentation as ready for buyers.
PHARMORIS must not be released or presented as ready for buyers while critical security risks remain, the deployed version cannot be identified or authentication can be bypassed.
The same stop applies when tenant or role authority is not enforced by server controls, migration and restore cannot be evidenced, source claims exceed operational proof or supplier and adopter responsibilities are conflated.
This gate protects buyers from a polished interface being mistaken for completed security, governance, data or deployment assurance.
Identity and authority
Authentication, roles enforced by the server and tenant boundaries need evidence in the version under review.
Release blockerRecoverability
Migration, backup and restore claims need controlled evidence rather than architectural expectation.
Release blockerSource and responsibility
Source rights, provenance and the division between supplier and adopter duties must remain explicit.
Release blocker03 · Buyer context
Assurance becomes specific at the institutional boundary.
A prospective adopter must assess its own intended use, information flows, users, integrations, local policies, clinical safety responsibilities, procurement route and risk acceptance.
Supplier evidence can support that work, but it does not grant local approval or remove the adopter's responsibility. Requirements for each customer should be handled through configuration, personas and source adapters rather than product forks.
The useful next step is a bounded evidence request against one workflow and one proposed operating context.
- Podcast appearance. AI Ethics Now / University of Warwick IATL. AI and Accountability: When Does a Suggestion Become a Decision?. 23 August 2026.
- Contributed opinion. TechRadar Pro. Five questions to test whether an AI stack is truly under your control. 11 August 2026.
- Founder commentary. ET Pharma. India’s pharma quality reset will be won after the inspector leaves. 4 August 2026.
- NEUVIOR analysis. NEUVIOR Insights. From pilot theatre to financial grip: how NHS CFOs should evaluate AI in medicines optimisation. 18 March 2026.
- NEUVIOR analysis. NEUVIOR Insights. NHS digital programmes do not fail on dashboards. They fail on deployment. 20 March 2026.
- Expert commentary. Manufacturing Chemist. NICE approval is not enough: why the UK's next medicines challenge is operational delivery. 4 June 2026.
- Founder commentary. PharmaTimes. How we roll. 10 June 2026.
- Editorial roundup. Digital Health. Digital Health Coffee Time Briefing. 26 May 2026.
Classified public record
ANALYSIS + EVIDENCE BOUNDARY
Read the argument. Verify the product separately.
Published analysis can explain why governance matters. It cannot evidence security, clinical authority, certification, product readiness or local approval. Use the dated NEUVIOR records for that.
AI and Accountability: When Does a Suggestion Become a Decision?
Varun Sharma joins AI Ethics Now to examine false confidence, human responsibility and the point where AI assisted suggestions become accountable decisions.
Hear where an AI suggestion becomes a decisionFive questions to test whether an AI stack is truly under your control
In TechRadar Pro, Varun Sharma sets out five tests for enterprise AI control across provenance, infrastructure, legal authority and safe exit.
Test provenance, control and safe exitFrom pilot theatre to financial grip: how NHS CFOs should evaluate AI in medicines optimisation
NHS finance leaders do not need another AI pitch. They need a disciplined way to decide whether a technology can release value within the financial rules they are already being held to.
See how a finance leader should test an AI claim
NEUVIOR Insights and After Publication reflections are company or founder analysis. Publisher records evidence publication, not endorsement, adoption, product readiness, savings or clinical outcomes.
Make the next step useful
Bring the problem that needs a clearer decision.
Tell us what is stuck, what decision you need to make and what a better outcome would change. We will connect you to the most relevant NEUVIOR, PHARMORIS, media or investor route.